Urothelial Carcinoma — Trials

Urothelial Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

623 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 236
Recruiting: 118
Ph III recruiting: 14
Growth YoY: +37.5%
Industry share: 33%
Top sponsor: National Cancer Institute (NCI)
Termination share: 44.7%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (99)

clinicaltrialsPublishedShowing 51–61 of 61 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00749892	Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer	completed	Phase 2	34	M.D. Anderson Cancer CenterOTHER	1	Sep 10, 2020	clinicaltrials
NCT02178241	Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery	completed	Phase 2	26	National Cancer Institute (NCI)NIH	2	Dec 16, 2019	clinicaltrials